
Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – HC Wainwright raised their FY2026 earnings per share estimates for Galectin Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($0.26) for the year, up from their prior estimate of ($0.30). The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.16) EPS.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01.
Get Our Latest Research Report on GALT
Galectin Therapeutics Stock Down 5.7%
NASDAQ:GALT opened at $2.81 on Wednesday. The business’s 50 day moving average is $3.55 and its two-hundred day moving average is $3.22. Galectin Therapeutics has a 52 week low of $2.03 and a 52 week high of $7.13. The company has a market cap of $185.07 million, a PE ratio of -8.26 and a beta of 0.53.
Institutional Investors Weigh In On Galectin Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of GALT. Commonwealth Equity Services LLC boosted its stake in Galectin Therapeutics by 13.1% in the third quarter. Commonwealth Equity Services LLC now owns 460,296 shares of the company’s stock valued at $1,786,000 after acquiring an additional 53,183 shares during the period. Vivaldi Capital Management LP grew its holdings in shares of Galectin Therapeutics by 26.7% during the first quarter. Vivaldi Capital Management LP now owns 258,584 shares of the company’s stock valued at $721,000 after purchasing an additional 54,514 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Galectin Therapeutics in the 1st quarter worth approximately $413,000. Goldman Sachs Group Inc. boosted its position in Galectin Therapeutics by 85.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 138,558 shares of the company’s stock valued at $538,000 after purchasing an additional 64,004 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Galectin Therapeutics during the 2nd quarter valued at approximately $491,000. Institutional investors and hedge funds own 11.68% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
